Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter single-arm phase II clinical trial to evaluate the efficacy and safety
of olaparib in patients diagnosed of advanced triple negative breast cancer (TNBC) with
methylation of BRCA1 and/or BRCA2 promoters assessed in DNA from metastatic lesions and
absence of BRCA1 and 2 germline mutations.